AUTL
Price
$2.31
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
617.44M
33 days until earnings call
OCUL
Price
$9.22
Change
-$0.24 (-2.54%)
Updated
Jun 27 closing price
Capitalization
1.47B
44 days until earnings call
Interact to see
Advertisement

AUTL vs OCUL

Header iconAUTL vs OCUL Comparison
Open Charts AUTL vs OCULBanner chart's image
Autolus Therapeutics
Price$2.31
Change-$0.00 (-0.00%)
Volume$2.09M
Capitalization617.44M
Ocular Therapeutix
Price$9.22
Change-$0.24 (-2.54%)
Volume$4.21M
Capitalization1.47B
AUTL vs OCUL Comparison Chart in %
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. OCUL commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a StrongBuy and OCUL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (AUTL: $2.32 vs. OCUL: $9.23)
Brand notoriety: AUTL and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 69% vs. OCUL: 177%
Market capitalization -- AUTL: $617.44M vs. OCUL: $1.47B
AUTL [@Biotechnology] is valued at $617.44M. OCUL’s [@Biotechnology] market capitalization is $1.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, AUTL is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 6 bullish TA indicator(s).

  • AUTL’s TA Score: 5 bullish, 5 bearish.
  • OCUL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than AUTL.

Price Growth

AUTL (@Biotechnology) experienced а +12.62% price change this week, while OCUL (@Biotechnology) price change was +13.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

AUTL is expected to report earnings on Jul 31, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.47B) has a higher market cap than AUTL($617M). OCUL YTD gains are higher at: 8.080 vs. AUTL (-1.277). OCUL has higher annual earnings (EBITDA): -176.35M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. OCUL (350M). AUTL has less debt than OCUL: AUTL (57.7M) vs OCUL (76.2M). OCUL has higher revenues than AUTL: OCUL (59.6M) vs AUTL (9.01M).
AUTLOCULAUTL / OCUL
Capitalization617M1.47B42%
EBITDA-226.02M-176.35M128%
Gain YTD-1.2778.080-16%
P/E RatioN/AN/A-
Revenue9.01M59.6M15%
Total Cash517M350M148%
Total Debt57.7M76.2M76%
FUNDAMENTALS RATINGS
AUTL vs OCUL: Fundamental Ratings
AUTL
OCUL
OUTLOOK RATING
1..100
2113
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3938
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (40) in the Biotechnology industry is in the same range as OCUL (54) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as AUTL (97) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as AUTL (39) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLOCUL
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TINGX26.090.17
+0.66%
Thornburg International Growth I
QCACX42.60N/A
N/A
Federated Hermes MDT All Cap Core C
PPQMX5.97N/A
N/A
Principal MidCap Growth III R3
MRCEX12.42N/A
N/A
Meridian Hedged Equity C
JDESX45.19N/A
N/A
JPMorgan US Research Enhanced Equity I

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+0.43%
CRSP - AUTL
47%
Loosely correlated
+1.69%
OCUL - AUTL
45%
Loosely correlated
-2.43%
ERAS - AUTL
45%
Loosely correlated
+1.98%
IMCR - AUTL
43%
Loosely correlated
-2.59%
ABEO - AUTL
43%
Loosely correlated
-2.54%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-2.43%
EYPT - OCUL
56%
Loosely correlated
-6.94%
DNLI - OCUL
55%
Loosely correlated
-2.77%
CRNX - OCUL
52%
Loosely correlated
-1.22%
RNA - OCUL
51%
Loosely correlated
-2.68%
YMAB - OCUL
51%
Loosely correlated
-1.88%
More